Research
Hormonal
Tirzepatide (5-15 mg weekly) significantly reduces body weight and HbA1c in patients with Type 2 Diabetes and obesity, outperforming semaglutide, insulin degludec, and insulin glargine.
Tirzepatide is a once-weekly injection for T2DM and obesity that works by mimicking gut hormones (GIP and GLP-1) to improve insulin sensitivity and reduce appetite. It produces greater weight loss and blood sugar control than existing GLP-1 drugs like semaglutide or insulin. Start with a low dose to manage side effects, titrating up every few weeks.
StrongSupportsHIGH confidence
Tirzepatide significantly outperformed dulaglutide, semaglutide, degludec, and glargine in terms of its effects on postprandial and fasting blood glucose levels as well as the likelihood that patients using it would experience a decrease in HbA1c
Why this rating
Based on multiple Phase 3 RCTs (SURPASS 1-5, SURMOUNT-1) with large sample sizes.
Source
Tirzepatide: A Promising Drug for Type 2 Diabetes and Beyond
Palak Dutta et al. · Cureus · 2023
narrative_reviewCited 24×
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →